Skip to content
Open in App
Fresenius SE logo

Fresenius SE

web2

Fresenius SE & Co. KGaA, a health care company, provides products and services for chronically...

Symbol · FSNUY
Company profile

About

Fresenius SE & Co. KGaA, a health care company, provides products and services for chronically ill patients in North America, Europe, the Asia-Pacific, Latin America, and Africa. It operates through Fresenius Kabi and Fresenius Helios segments. The Fresenius Kabi segment offers products for therapy and care of critically and chronically ill patients, including biopharmaceuticals, clinical nutrition, MedTech products, intravenously administered generic drugs, and IV fluids. It also provides biosimilar drugs; enteral and parenteral nutrition products; and medical technologies that include disposables, infusions pumps, apheresis machines, cell therapy devices, and other products. The Fresenius Helios segment operates hospitals, medical care centers, occupational health centers, prevention centers, and outpatient health centers, as well as provision of medical diagnostics. The company has a strategic collaboration with SAP SE and Avelios Medical GmbH for the development of a cloud-native, modular hospital information system that enables digitalization of clinical and administrative processes with AI integration. The company was formerly known as Fresenius SE and changed its name to Fresenius SE & Co. KGaA in January 2011. Fresenius SE & Co. KGaA was founded in 1912 and is based in Bad Homburg vor der Höhe, Germany.

Explore by sector

Explore this sector

Market identity

Exchange listings

Listing identities only. Orbitrum does not publish live prices or market performance on this public profile.

Progress

Roadmap

Fresenius establishes a corporate venture fund of more than €200 million

KEY STEP

On July 23, 2026, Fresenius established Fresenius Ventures with an intended investment volume of more than €200 million over five years, targeting growth fields adjacent to its Biopharma, MedTech, and Care Provision platforms.

Roadmap reference

FDA approves Fresenius Kabi rituximab biosimilar for the United States

KEY STEP

On August 3, 2026, the FDA approved a rituximab biosimilar developed by Dr. Reddy’s Laboratories. Fresenius Kabi holds exclusive commercialization rights in the United States.

Roadmap reference

Fresenius reduces Fresenius Medical Care stake to about 25 percent

KEY STEP

On August 20, 2026, Fresenius agreed to sell approximately 7.8 million Fresenius Medical Care shares for about €300 million, reducing its holding from roughly 28.6 percent to about 25.0 percent while remaining the largest shareholder.

Roadmap reference
People

Company team

WK

Wolfgang Kirsch

Independent Chairman of Supervisory Board

Company leadership profile.

MD

Michael Diekmann

Independent Deputy Chairman of the Supervisory Board

Company leadership profile.

GG

Grit Genster

Independent Deputy Chairperson of the Supervisory Board

Company leadership profile.

GE

Gerd E. Krick

Honorary Chairman of Supervisory Board

Company leadership profile.

SZ

Susanne Zeidler

Independent Member of the Supervisory Board

Company leadership profile.

IL

Iris Low-Friedrich

Independent Member of Supervisory Board

Company leadership profile.

OR

Oscar Romero De Paco

Independent Member of Supervisory Board

Company leadership profile.

BB

Bernd Behlert

Independent Member of Supervisory Board

Company leadership profile.

CZ

Christoph Zindel

Independent Member of Supervisory Board

Company leadership profile.

HM

Holger Michel

Independent Member of Supervisory Board

Company leadership profile.

CG

Carsten Georg

Members of the Supervisory Board

Company leadership profile.

RK

Ralf Kiesslich

Member of the Supervisory Board

Company leadership profile.

TL

Tania Lara Campana

Supervisory Board Member

Company leadership profile.

Expert coverage

2 experts evaluated Fresenius SE.

Orbitrum research

Experts evaluating Fresenius SE

Explore the public profiles of experts who have evaluated this project.

Orbitrum Academy

Learn how to read a project assessment